Theravance

Latest news

• FDA Approves Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease (COPD)
  9 November 2018
• Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of Yupelri (revefenacin) at the 2018 CHEST Annual Meeting
  11 October 2018
• Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of Yupelri (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018
  11 September 2018
• Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
  29 January 2018
• Theravance Biopharma and Mylan Submit NDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
  13 November 2017
• Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD)
  19 July 2017
• Theravance Biopharma Announces FDA Approval of Expanded Label for Vibativ (telavancin)
  9 May 2016
• FDA Approves Vibativ for Hospitalized Patients with Bacterial Pneumonia
  21 June 2013
• Theravance and Astellas Announce FDA Approval of Vibativ (telavancin) for the Treatment of Complicated Skin and Skin Structure Infections
  13 September 2009
• FDA Accepts for Review Theravance's Complete Response Submission for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
  25 April 2009

Drugs Associated with Theravance, Inc.

Theravance, Inc. manufactures, markets and/or distributes more than 2 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.